Critical Drug & Food Interactions
Quiz Game

The 2026 PTCE (effective January 2026) most commonly tests: (1) Grapefruit juice + statins (CYP3A4 inhibition → rhabdomyolysis), (2) Warfarin + NSAIDs (protein displacement + GI ulcer + platelet inhibition = fatal hemorrhage), (3) SSRIs + MAOIs (serotonin syndrome), (4) Sildenafil + nitrates (catastrophic hypotension — absolute contraindication), (5) Spironolactone + TMP-SMX (hyperkalemia → cardiac arrest), (6) Clopidogrel + omeprazole (CYP2C19 inhibition — prodrug not activated), (7) Metronidazole + alcohol (disulfiram-like reaction), (8) Opioids + benzodiazepines (FDA Black Box — respiratory depression). Interactions appear across Domain 1 (Medications, 35%) and Domain 3 (Patient Safety, 26.25%). Note: the 2026 update removed NTI drugs as a standalone testable category, but drug interactions involving these drugs remain high-yield.

Because grapefruit furanocoumarins are "suicide inhibitors" — they permanently destroy the CYP3A4 enzymes in the intestinal wall, rather than reversibly blocking them. The body must synthesize brand-new enzymes from scratch, which takes up to 72 hours (3 full days). A patient who drinks grapefruit at 8am and takes simvastatin at 8pm is still at full risk. The only solutions are: eliminate grapefruit entirely, or switch the patient to pravastatin or rosuvastatin, which are metabolized through CYP3A4-independent pathways.

Minimum 5 full weeks (35 days) after the last dose of fluoxetine before starting any MAOI. This is far longer than the 2-week washout required for all other SSRIs. The reason is fluoxetine's uniquely long half-life — its active metabolite norfluoxetine remains in systemic circulation for weeks after the last dose. Initiating an MAOI too soon risks life-threatening serotonin syndrome: rapid onset of agitation, profuse sweating, tachycardia, muscle rigidity, hyperreflexia, clonus, and potentially fatal hyperthermia.

Only the FREE (unbound) drug is pharmacologically active. Drugs bound to plasma proteins like albumin are inactive — they cannot reach target receptors, cause effects, or produce toxicity. Warfarin is 99% protein-bound, meaning only 1% is active at any given time. When a competing drug (like aspirin) displaces warfarin from albumin, the free warfarin fraction doubles or triples instantly — even though the total amount of drug in the body hasn't changed. This means a 100–200% increase in active anticoagulant, which can cause fatal internal bleeding.

Spironolactone (a potassium-sparing diuretic used in heart failure) blocks aldosterone, causing the kidneys to retain potassium. Trimethoprim — the TMP in TMP-SMX (Bactrim) — independently mimics a potassium-sparing diuretic in the kidney's distal nephron. Combined, especially in elderly patients, they create a double blockade that prevents potassium excretion. The resulting hyperkalemia (dangerously high blood potassium) disrupts cardiac electrical conduction, leading to lethal ventricular arrhythmias and sudden cardiac death. A landmark study found a 12-fold increase in hospitalizations for hyperkalemia when elderly heart failure patients on spironolactone received TMP-SMX for UTIs rather than a safer antibiotic like nitrofurantoin.

A narrow therapeutic index (NTI) drug has a very small window between its effective dose and its toxic dose — a 5–10% change in blood concentration can push a patient from therapeutic to critically poisoned. Key NTI drugs include digoxin, lithium, warfarin, phenytoin, cyclosporine, and levothyroxine. Important 2026 update: PTCB removed NTI drugs as a standalone knowledge category from the January 2026 exam. However, these drugs still appear throughout drug interaction and patient safety questions — so knowing their toxicity signs and interactions remains essential. Digoxin toxicity → yellow/green halos around lights; lithium toxicity → tremors and confusion; warfarin toxicity → unusual or uncontrollable bleeding.

Clopidogrel (Plavix) is a prodrug — it is pharmacologically inactive when swallowed. The liver enzyme CYP2C19 must convert it into its active blood-thinning form. Omeprazole and esomeprazole (both common PPIs) are potent CYP2C19 inhibitors. When a patient takes clopidogrel + omeprazole, the conversion never happens — clopidogrel remains inactive, and the patient receives no antiplatelet protection despite taking the medication faithfully. This is dangerous for patients who need clopidogrel for stroke prevention or after coronary stent placement. The exam-tested solution: switch to pantoprazole (Protonix), which has minimal CYP2C19 inhibitory activity and can be safely combined with clopidogrel.

Both opioids and benzodiazepines (like alprazolam/Xanax, diazepam/Valium, or lorazepam/Ativan) independently suppress the brainstem's respiratory drive — the involuntary signal that keeps us breathing. Individually, each class can cause sedation and slowed breathing at high doses. Combined, their effects are synergistic (not just additive), meaning the combined respiratory depression is far greater than the sum of the individual effects. This makes it easy to fatally overdose on combinations of doses that would be individually safe. The FDA issued a Black Box Warning in 2016 requiring labeling on all opioid and benzodiazepine prescriptions warning of "profound sedation, respiratory depression, coma, and death." Pharmacy technicians should flag any prescription presenting both drug classes together and alert the pharmacist immediately.

Disulfiram (Antabuse) is a drug used in alcohol dependence — it blocks acetaldehyde dehydrogenase, the enzyme that breaks down acetaldehyde (alcohol's toxic intermediate byproduct). When a patient on disulfiram drinks alcohol, acetaldehyde accumulates and causes immediate, intense flushing, nausea, vomiting, sweating, tachycardia, and headache. Metronidazole (Flagyl) produces an identical reaction through the same mechanism, even though it is an antibiotic prescribed for infections like bacterial vaginosis, C. difficile, and H. pylori. Patients must avoid ALL alcohol — including mouthwash, extracts, and alcohol-containing medications — for 48–72 hours after their LAST dose of metronidazole. This is a commonly tested counseling point on the PTCE.

Acetaminophen (Tylenol) is the preferred — not risk-free — choice. It's preferred because it doesn't create GI ulcers, doesn't permanently disable platelets, and doesn't displace warfarin from protein binding sites the way NSAIDs do. However, at high sustained doses (more than 2,000 mg/day for several consecutive days), acetaminophen's toxic metabolites can inhibit the liver enzymes that break down warfarin, causing warfarin to accumulate and the INR to rise dangerously. The key counseling point: acetaminophen is acceptable at normal doses, but a warfarin patient planning to take maximum-strength Tylenol around the clock should first consult the pharmacist, who should notify the prescriber.